Posted by Michael Wonder on 27 Jan 2025
FDA approves Leqembi (lecanemab-irmb) IV maintenance dosing for the treatment of early Alzheimer's disease
26 January 2025 - Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment.
Eisai and Biogen announced today that the US FDA has approved the supplemental biologics license application for once every four weeks lecanemab-irmb (Leqembi) intravenous maintenance dosing.
